Nemera launches DuoSpray, strengthening its systemic intranasal delivery platform portfolio

Nemera announces the launch of DuoSpray in September 2026, a bidose nasal spray platform designed to support nasal drug-device combination product development for systemic drug administration.

The nasal route represents a non-invasive, needle free administration alternative for systemic therapies, offering rapid onset of action and enabling self-administration without healthcare professional intervention.

The launch of DuoSpray reflects Nemera’s strategy to provide pharmaceutical companies with flexible, commercially ready platform solutions that help accelerate the adoption of systemic intranasal therapies.

This new solution complements the commercially available UniSpray platform, strengthening Nemera’s comprehensive offering in systemic nasal drug delivery.

“The launch of DuoSpray is an important step in Nemera’s ambition to become the partner of choice for systemic intranasal drug delivery. By combining complementary liquid platforms with expanding dry powder capabilities, we are building a comprehensive portfolio of intranasal solutions that helps pharmaceutical companies bring innovative therapies to patients faster and with reduced development risk. Our goal is not only to provide devices, but to support our customers from early development through successful commercialization.” says Dimitri Grasswill, Vice President Ear, Nose and Throat (ENT).